Benefit of monoclonal antibodies in early treatment of COVID-19 after lung transplantation: a retrospective analysis in two centres

Research output: Contribution to journal › Letter › Contributed › peer-review

Contributors

  • Jens Gottlieb - , Leibniz University Hannover (LUH) (Author)
  • Martin Kolditz - , Department of Internal Medicine I, Division of Pulmonology, University Hospital Carl Gustav Carus Dresden, Both authors contributed equally (Author)
  • Nils Gade - , University Hospital Münster (Author)
  • Tobias Welte - , Leibniz University Hannover (LUH) (Author)
  • Nikolaus Kneidinger - , German Center for Lung Research (DZL) (Author)

Abstract

Treatment with monoclonal antibodies was associated with improved survival in COVID-19 after lung transplantation (LTx). Age was a negative independent predictor of survival in this cohort of 133 COVID-19 cases after LTx. https://bit.ly/3kx5CBw

Details

Original languageEnglish
Article number2200124
JournalThe European respiratory journal
Volume60
Issue number1
Publication statusPublished - Jul 2022
Peer-reviewedYes

External IDs

PubMedCentral PMC9301052
ORCID /0000-0001-6022-6827/work/127318517
Scopus 85134854910
WOS 000880183800011

Keywords

Keywords

  • Antibodies, Monoclonal/therapeutic use, COVID-19/therapy, Humans, Lung Transplantation, Retrospective Studies